Type(s) de contenu et mode(s) de consultation : Texte noté : électronique

Titre(s) : Hypertension [Texte électronique] : a companion to Brenner and Rector's the kidney / [edited by] Suzanne Oparil, Michael A. Weber

Édition : 2nd ed.

Publication : Philadelphia : Elsevier Mosby, cop. 2005

Description matérielle : 1 ressource dématérialisée

Note(s) : Companion v. to Brenner & Rector's the kidney / edited by Barry M. Brenner. 7th ed. c2004. - Includes bibliographical references and index
This revised and updated 2nd Edition provides a logical, practical framework for managing patients with hypertension. Leading experts discuss all aspects of the field -- from pathophysiology, pharmacological treatments, and lifestyle modifications to secondary hypertension and cardiovascular complications. The book assesses the risks of specific pharmacological treatments, offers expert analysis of recent clinical trials, delivers strategies for managing patients with comorbid conditions such as diabetes, renal disease, and ischemic heart disease, and explains the role of vascular biology in the pathogenesis of hypertension

Autre(s) auteur(s) : Weber, Michael A. (1942-....)  Voir les notices liées en tant qu'auteur
Oparil, Suzanne. Fonction indéterminée  Voir les notices liées en tant qu'auteur

Sujet(s) : Hypertension artérielle  Voir les notices liées en tant que sujet
Hypertension artérielle -- Complications (médecine)  Voir les notices liées en tant que sujet

Indice(s) Dewey :  616.132 (23e éd.) = Hypertension (médecine)  Voir les notices liées en tant que sujet

Identifiants, prix et caractéristiques : ISBN 9780721602585

Identifiant de la notice  : ark:/12148/cb446501638

Notice n° :  FRBNF44650163 (notice reprise d'un réservoir extérieur)

Table des matières : Sect. 1. Background and history. A history of hypertension treatment ; The National High Blood Pressure Education Program ; Epidemiology of hypertension ; sect. 2. Pathophysiology. Pathophysiology of hypertension ; Blood pressure genetics ; The sympathetic nervous system in acute and chronic blood pressure elevation ; Environmental and psychosocial stress in hypertension onset and progression ; Renin ; Angiotensin-converting enzymes: properties and function ; Angiotensin-(1-7) ; The angiotensin receptors: AT₁ and AT₂ ; Aldosterone and mineralocorticoids ; The role of insulin resistance and compensatory hyperinsulinemia in patients with essential hypertension ; Remodeling of resistance arteries in hypertension ; Clinical applications of arterial stiffness in hypertension ; Endothelium in hypertension: nitric oxide.
Endothelin in hypertension ; Natriuretic peptides ; Vasodilator peptides: CGRP, substance P, and adrenomedullin ; The Kallikrein-Kinin System as a regulator of cardiovascular and renal function ; sect. 3. Target organ damage/cardiovascular events. The concept of total risk ; New interpretations of blood pressure: the importance of pulse pressure ; Coronary atherosclerotic sequelae of hypertension ; Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension ; Renal protection in chronic kidney disease ; sect. 4. Diagnosis. Initial evaluation and follow-up assessment ; Prognostic and diagnostic value of ambulatory blood pressure monitoring ; White-coat hypertension ; sect. 5. Treatment: general considerations. The blood pressure lowering treatment trialists' collaboration (BPLTTC).
The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) ; The LIFE study ; The VALUE trial ; Main results from VALUE ; Clinical outcome trials of hypertension with angiotensin receptor blockers ; ACE inhibitor trials: effects in hypertension ; Critical assessment of hypertension guidelines ; Current prescribing practices ; Calcium channel blockers: controversies, lessons, and outcomes ; Nursing clinics in the management of hypertension ; Community outreach ; Medication adherence for antihypertensive therapy ; sect. 6. Diet and nutrition. Diet: micronutrients ; Dietary approaches to hypertension management: the DASH studies ; Obesity and hypertension: impact on the cardiovascular and renal systems ; Alcohol and hypertension ; Obesity in hypertension: the role of diet and drugs ; Exercise and hypertension.
Sect. 7. Pharmacologic treatment. Initial choices in the treatment of hypertension ; Pharmacokinetics of antihypertensive drugs ; Fixed combination antihypertensive therapy ; Chronotherapeutics in the treatment of hypertension ; sect. 8. Comorbid conditions and special populations in hypertension. Diabetes mellitus and the cardiovascular metabolic syndrome: reducing cardiovascular and renal events ; Hypertension in patients on renal replacement therapy ; Ischemic heart disease in hypertension ; Hypertension in the elderly ; Management of hypertension in Black populations ; Hypertension in pregnancy ; Hypertension in children ; Resistant hypertension ; Orthostatic hypotension and autonomic dysfunction syndromes.
Sect. 9. Individual drug classes. How antihypertensive drugs get approved in the United States ; Diuretics: mechanisms of action ; [beta]-adrenergic blockers ; [alpha]-adrenoceptor blockers ; Angiotensin-converting enzyme inhibitors ; Calcium antagonists ; Angiotensin II receptor antagonists ; Direct-acting smooth muscle vasodilators and adrenergic inhibitors ; Endothelin antagonists ; Mineralocorticoid receptor antagonists ; Vasopeptidase inhibitors ; Renin inhibitors ; sect. 10. Secondary hypertension. Obstructive sleep apnea and hypertension ; Renovascular hypertension: diagnosis and treatment ; Adrenal cortex hypertension ; Phoechromocytoa: detection and management ; Anesthesia and hypertension ; Management of hypertensive emergencies and urgencies ; Aggressive blood pressure targets; developing effective algorithms.